Market Place
Sourcing Support
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics
27 Nov 2023 //
PR NEWSWIRE
Exclusive: Aeglea rebrands to Spyre, names new CEO in IBD race
27 Nov 2023 //
ENDPTS
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
27 Jul 2023 //
PR NEWSWIRE
Aeglea sells off rare disease asset to Immedica for $15M
27 Jul 2023 //
FIERCE BIOTECH
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
22 Jun 2023 //
PR NEWSWIRE
Spyre, a new biotech spinout, launches via merger with Aeglea
21 Jun 2023 //
BIOPHARMADIVE
Aeglea lays off more staff, seeks exit in face of rocky data
12 Apr 2023 //
FIERCE BIOTECH
Aeglea`s layoffs curb spending, but cash crunch still on cards
03 Mar 2023 //
FIERCE BIOTECH
Aeglea BioTherapeutics Appoints Linda Neuman, M.D to Chief Medical Officer
15 Nov 2022 //
PRNEWSWIRE
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
PRNEWSWIRE
Aeglea replaces CEO as company is set to cut more employees, change strategy
26 Aug 2022 //
ENDPTS
Aeglea culls workers, shifts pipeline focus after knockback by FDA
25 Aug 2022 //
FIERCEBIOTECH
Aeglea BioTherapeutics Announces EMA Validation of MAA for Pegzilarginase
18 Aug 2022 //
PRNEWSWIRE
Aeglea BioTherapeutics Gets Refusal to File Letter From FDA for Pegzilarginase
03 Jun 2022 //
MARKETWATCH
Aeglea Bio Presents Data from PEACE PIII Study of Pegzilarginase in A1-D
11 Apr 2022 //
PRNEWSWIRE
Aeglea Bio to Present Additional Data from PEACE Phase 3 Study of Pegzilarginase
29 Mar 2022 //
PRNEWSWIRE
Aeglea Bio Reports Q4 and FY 2021 Financial Results
08 Mar 2022 //
PRNEWSWIRE
Aeglea BioTherapeutics Withdraws Public Offering
10 Feb 2022 //
PRESS RELEASE
Aeglea BioTherapeutics Announces Proposed Public Offering
09 Feb 2022 //
PRESS RELEASE
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3
06 Dec 2021 //
PRESS RELEASE
Aeglea`s engineered enzyme flops outcomes test in rare metabolic disease
06 Dec 2021 //
ENDPTS
Aeglea Bio to Report Phase 3 Topline Results of Pegzilarginase
05 Dec 2021 //
PRNEWSWIRE
Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021
04 Nov 2021 //
PRNEWSWIRE
Aeglea BioTherapeutics Completes Patient Randomization for PEACE
04 May 2021 //
PRNEWSWIRE
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement
22 Mar 2021 //
PRNEWSWIRE
Aeglea Receives FDA Rare Pediatric Disease Designation for ACN00177
01 Dec 2020 //
PRNEWSWIRE
Aeglea nabs orphan drug designation for enzyme treatment
26 Oct 2020 //
SCIENCEBOARD
Aegle Therapeutics Announces Award of Grant by U.S. ("DoD") AGLE-102
08 Oct 2020 //
PRNEWSWIRE
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency
05 Oct 2020 //
BIOSPACE
FDA Grants Fast Track Status to Aegle Therapeutics` AGLE-102 for the Treatment
01 Oct 2020 //
PRNEWSWIRE
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase
26 May 2020 //
GLOBENEWSWIRE
Aeglea BioTherapeutics Announces Proposed Public Offering
27 Apr 2020 //
GLOBENEWSWIRE
